Home Featured Page 164

Featured

Latest

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon

Logan Davidson – American Ibogaine, State Strategy, and the Future of Psychedelic Policy

Areyto Boriken – Ethnobotanical Adventure

The Ram Dass Institute of Psychedelic Studies with The Dying Inaugural Event on Maui

PT332 – James Lanthier – Patentability, Capitalism, and The Next Generation...

Incannex to Present at the H.C. Wainwright First Annual Mental Health...

Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping...

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st...

Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration...

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

CB Therapeutics granted a new patent that will help further provide...

Wake Network, Inc. Receives Certificate of Drug Registration for Microdose Formulation...

Diamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of...

Gilgamesh Announces Clinical Candidates For Two Programs With First In Human...

1...163164165...303 Page 164 of 303

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the...

Logan Davidson – American Ibogaine, State Strategy, and the Future of...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.